- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Cipla and Kemwell Collaborate on Lung Disease Biosimilars
Cipla, a medicines developer and retailer, and Kemwell Biopharma, a contract manufacturer, intend to produce biosimilars for lung disorders.
Two India-based companies said they have formed a partnership to develop biosimilars for respiratory disease. Their goal is to sell these biosimilars in global markets.
Cipla, based in Mumbai, and Kemwell Biopharma, of Bengaluru, will pair their complementary strengths in product development, clinical development, regulatory filings, manufacturing, and commercialization to develop the biosimilars pipeline, they said.
“This development reinforces our strength as leaders in respiratory therapy and is in line with our aspiration of global lung leadership,” Umag Vohra, managing director and CEO of Cipla, said in a statement.
Cipla is a lung disease specialist with products on the international markets for asthma, chronic obstructive pulmonary disease, allergic rhinitis, and other conditions. The company also produces medicines across multiple other therapeutic categories, including diabetes, women’s health, and tuberculosis.
Besides India, the company has facilities in Africa and North America. The company’s plant in Durban, South Africa, was recently vandalized and looted during the political violence over the jailing of former president Jacob Zuma, but has since reopened.
Kemwell is a contract biologics development and manufacturing company. Kemwell boasts facilities designed in collaboration with German expertise and has partnered with Bayer, GlaxoSmithKline, Merck, Novartis, and Pfizer, according to its website. Kemwell has manufacturing plants in Sweden.
For companies in the developing world, it is important to reassure international clients and markets that facilities and products meet high standards.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.
